Furthermore, in malignant lymphoma, glioma, and kidney cancer, higher CD163 expression on TAMs is associated with worse clinical prognosis; however, no correlation exists between clinical prognosis and the number of CD204-expressing TAMs9, 10, CD204, also known as Class A scavenger receptor (SRA), has been shown to participate in the pathogenesis of atherosclerosis and the pattern recognition of pathogen infection11. This evidence concerns the gene CD163 and glioma.